Pfizer Halts Sutent's Phase III in Hepatocellular Carcinoma
This article was originally published in The Pink Sheet Daily
Executive Summary
Failure is the second in two months for Sutent, which is a lynchpin of Pfizer's oncology strategy.
You may also be interested in...
A Management Shake-Up At Pfizer Raises Questions
2011 is likely to be a defining year for Pfizer and the Big Pharma has hit the ground running. In early December, the board of directors announced a management shake-up, as CEO Jeff Kindler resigned unexpectedly and the board simultaneously elected veteran Pfizer executive Ian Read to replace him. In the ensuing weeks, the board also named a new non-executive chairman, George Lorch, former chairman and CEO of the diversified conglomerate Armstrong Holdings. In addition, it consolidated leadership of several business units and appointed some of those leaders to its executive committee.
A Management Shake-Up At Pfizer Raises Questions
2011 is likely to be a defining year for Pfizer and the Big Pharma has hit the ground running. In early December, the board of directors announced a management shake-up, as CEO Jeff Kindler resigned unexpectedly and the board simultaneously elected veteran Pfizer executive Ian Read to replace him. In the ensuing weeks, the board also named a new non-executive chairman, George Lorch, former chairman and CEO of the diversified conglomerate Armstrong Holdings. In addition, it consolidated leadership of several business units and appointed some of those leaders to its executive committee.
Pfizer Seeks To Salvage Sutent For Lung Cancer
Company hopes development in patient subsets will save expansion plans for top-selling cancer drug.